CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the “John et al.” patent (Application No. 10/384,463), which covers methods of inhibiting mutant genes with double-stranded RNAs from 19 to 30 nucleotides in length. Since mutations in genes underscore the genetics of inherited disease and cancer, as well as broader aspects of human disease associated with genetic variations, the John et al. patent covers broad therapeutic applications of RNAi therapeutics.
